Metal Drugs and the Anticancer Immune Response
Open accessThe DOI matches its Crossref record; 1,300 of the 1,300 references it cites were found in a registry or an index.
Abstract
The immune system deploys a multitude of innate and adaptive mechanisms not only to ward off pathogens but also to prevent malignant transformation ("immune surveillance"). Hence, a clinically apparent tumor already reflects selection for those malignant cell clones capable of evading immune recognition ("immune evasion"). Metal drugs, besides their well-investigated cytotoxic anticancer effects, massively interact with the cancer-immune interface and can reverse important aspects of immune evasion. This topic has recently gained intense attention based on combination approaches with anticancer immunotherapy (e.g., immune checkpoint inhibitors), a strategy recently delivering first exciting results in clinical settings. This review summarizes the promising but still extremely fragmentary knowledge on the interplay of metal drugs with the fidelity of anticancer immune responses but also their role in adverse effects. It highlights that, at least in some cases, metal drugs can induce long-lasting anticancer immune responses. Important steps in this process comprise altered visibility and susceptibility of cancer cells toward innate and adaptive immunity, as well as direct impacts on immune cell populations and the tumor microenvironment. On the basis of the gathered information, we suggest initiating joint multidisciplinary programs to implement comprehensive immune analyses into strategies to develop novel and smart anticancer metal compounds.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
2 retracted
Chattopadhyay, S., Dash, S. K., Mahapatra, S. K., Tripathy, S., Ghosh, T., Das, B., Das, D., Pramanik, P., & Roy, S. (2014) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-013-1085-2 · Cited by 50
RetractedChatterjee, S., Mookerjee, A., Basu, J. M., Chakraborty, P., Ganguly, A., Adhikary, A., Mukhopadhyay, D., Ganguli, S., Banerjee, R., Ashraf, M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007048 · Cited by 46
RetractedSiegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
The capsaicin receptor: a heat-activated ion channel in the pain pathway
Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., & Julius, D. (1997) · Nature · doi:10.1038/39807 · Cited by 9,107
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Research works printed but not linked: 47
- van der Most R. G., 2005, Discovery Medicine, 5, 265
- Alberts B., 2015, Mol. Biol. Cell
- Seliger B., 1996, Exp. Hematol., 24, 1275
- Fink D., 1996, Cancer Res., 56, 4881
- Yoshikawa A., 1997, Kobe J. Med. Sci., 43, 109
- 10.1007/s00775-018- 1546-8 · doi:10.1007/s00775-018-
- Rosenberg, B. In Advances in Antimicrobial and Antineoplastic Chemotherapy, University Park Press: Baltimore, 1972; Vol. 11.
- 10.1002/(SICI)1098-2264(199704)18:4<286::AID-GCC6>3.0.CO;2-X · doi:10.1002/(sici)1098-2264(199704)18:4<286::aid-gcc6>3.0.co;2-x
- Dempsey J. L., 1985, Cancer Res., 45, 2873
- Nio Y., 2000, Anticancer Res., 20, 3293
- Qin X., 2010, Cell. Mol. Biol. (Noisy- le-grand), 56, 1366
- Kleinerman E. S., 1980, Cancer Res., 40, 3099
- Lichtenstein A. K., 1986, Cancer Res., 46, 639
- 10.1002/1097-0142(19930215)71:4<1313::AID-CNCR2820710424>3.0.CO;2-# · doi:10.1002/1097-0142(19930215)71:4<1313::aid-cncr2820710424>3.0.co;2-#
- Yamaue H., 1991, J. Clin. Lab. Immunol., 35, 165
- 10.1002/(SICI)1097-0215(19971104)73:3<416::AID-IJC17>3.0.CO;2-A · doi:10.1002/(sici)1097-0215(19971104)73:3<416::aid-ijc17>3.0.co;2-a
- Jiang J., 2006, Anticancer Res., 26, 2237
- Ujiie T., 1989, Jpn. J. Exp. Med., 59, 17
- Maeda K., 2011, Anticancer Res., 31, 4569
- Miller W. H., 2002, Cancer Res., 62, 3893
- 10.1097/CJI.0b013e3181755deb · DOI
- Kreuser E. D., 1992, Semin. Oncol., 19, 73
- Magnarin M., 2000, Anticancer Res., 20, 2939
- Nardon C., 2014, Anticancer Res., 34, 487
- Hashimoto K., 1994, J. Rheumatol., 21, 1020
- Yan A., 1990, J. Rheumatol., 17, 47
- Wang X. D., 2009, Zhongguo Shi Yan Xue Ye Xue Za Zhi, 17, 533
- 10.1371/journal.pone.0100933 · DOI · Paper page
- Korbecki J., 2012, Acta Biochim. Polym., 59, 195
- 10.3109/1547691X.2014.996681 · DOI
- Desoize B., 2004, Anticancer Res., 24, 1529
- Sava G., 1985, Anticancer Res., 5, 249
- Boscolo P., 2004, Ann. Clin. Lab. Sci., 34, 299
- Brewer G. J., 2000, Clin. Cancer Res., 6, 1
- Redman B. G., 2003, Clin. Cancer Res., 9, 1666
- Pan Q., 2003, Mol. Cancer Res., 1, 701
- Lukasewycz O. A., 1982, J. Natl. Cancer Inst., 69, 489
- 10.1515/9783110470734-016 · doi:10.1515/9783110470734-016
- Eriksson M., 2009, Anticancer Res., 29, 11
- Signat B., 2011, Curr. Issues Mol. Biol., 13, 25
- Sonis S. T., 2004, J. Support. Oncol., 2, 21
- 10.1053/sonc.2002.35524 · doi:10.1053/sonc.2002.35524 · Paper page
- Juhn S. K., 2001, Int. Tinnitus J., 7, 72
- Boussios S., 2012, Ann. Gastroenterol., 25, 106
- Takeyama K., 2000, Int. J. Hematol., 71, 144
- Giles F. J., 1994, Curr. Opin. Hematol., 1, 256
- Lu J., 2017, Ochsner J., 17, 379
Cited by
Items 301–354 of 354
Alkaline-earth metal(II) complexes of salinomycin – spectral properties and antibacterial activity
Pantcheva, I. N., Petkov, N., Simova, S., Zhorova, R., & Dorkov, P. (2022) · Physical Sciences Reviews · doi:10.1515/psr-2021-0201 · Cited by 3
Antioxidant conjugated metal complexes and their medicinal applications
Roy, A., & Chinta, J. P. (2023) · Vitamins and hormones · doi:10.1016/bs.vh.2022.10.003 · Cited by 3
Red‐Light Photocatalytic Activation of Pt(IV) Anticancer Prodrugs Using Methylene Blue
Carrasco, A. C., Bajetto, G., Scoditti, S., Pieslinger, G. E., Gambino, F., Andrea, M. D., Sicilia, E., Martínez‐Martínez, V., Dell’Oste, V., & Salassa, L. (2024) · ChemCatChem · doi:10.1002/cctc.202401424 · Cited by 3
Mallea, M., Almendras, I., Gallardo, M., Roussel, P., Henry, N., Steinbrueck, A., Metzler‐Nolte, N., & Arancibia, R. (2025) · Polyhedron · doi:10.1016/j.poly.2025.117648 · Cited by 2
Mitochondria‐Targeted Molecular Tools in Precise Tumor Therapy
Wang, X., Tang, Y., & Li, Q. (2025) · Angewandte Chemie · doi:10.1002/ange.202511230 · Cited by 11
High Cytotoxicity of Ruthenium(II) and Gold(I) Bimetallic Complexes and Its Precursors
Blignaut, J., Visser, H. G., Fourie, E., & Schutte‐Smith, M. (2026) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.5c04993 · Cited by 2
DNA-targeting ruthenium(II) complexes that simultaneously induce tumor apoptosis and autophagy
Ling, Y., Hao, L., Liao, C., He, Y., Hu, Y., Peng, Z., Li, Z., Chen, L., Wang, Y., & Chen, J. (2026) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2026.113247 · Cited by 2
Investigation of the potential anticancer immune response for gold compounds
Bian, M., Wen, Z., Shi, J., & liu, W. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.112596 · Cited by 2
Lin, J., Pan, H. Y., Wu, K., Nan, J., Dai, J., Chang, Y., Shen, H., Ye, Q., Lu, H., Shen, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.202524246 · Cited by 2
Melounková, L., Syková, M., Jirásko, R., Jambor, R., Havelek, R., Peterová, E., Honzı́ček, J., & Vinklárek, J. (2021) · New Journal of Chemistry · doi:10.1039/d1nj03533a · Cited by 2
Banaspati, A., Raza, M. K., & Goswami, T. K. (2023) · ChemistrySelect · doi:10.1002/slct.202303130 · Cited by 2
Intranuclear assembly of leucine-rich peptides for selective death of osteosarcoma cells
Liu, S., Zhang, Q., Peng, X., Hu, C., Wang, S., & Sun, Y. (2024) · Biomaterials Science · doi:10.1039/d3bm02054a · Cited by 2
Shaira, A., Jaganyi, D., Mambanda, A., & Papo, T. R. (2025) · Polyhedron · doi:10.1016/j.poly.2025.117817 · Cited by 2
Making and Breaking—Insight into the Symmetry of Salen Analogues
Krupka, K. M., Banach, S., Pocheć, M., Panek, J. J., & Jezierska, A. (2023) · Symmetry · doi:10.3390/sym15020424 · Cited by 2
Cascade targeting strategy for antitumor transition metal complexes
Zheng, Y., Liu, W., Cao, Q., Tan, C., Xia, W., & Mao, Z. (2024) · Scientia Sinica Chimica · doi:10.1360/ssc-2024-0102 · Cited by 2
Monoclonal Antibodies in Clinical Trials for Breast Cancer Treatment
Shaik, R., Mounika, V. P. S., Begum, S., Rajkumar, A., Mallikarjun, B., Harshini, V. S., Kolure, R., Sreevani, B., & Thakur, S. (2025) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2024.0018 · Cited by 2
Zhang, C., Qi, F., Zheng, Y., Xia, X., Li, X., & Wang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.749119 · Cited by 2
“Meanwhile, TME heterogeneity was a pivotal determinant for therapeutic efficiency and exhibited different profiles during the process of tumor progression (10, 11).”
BackgroundShao, W., Sun, Y., Su, H., Sun, Q., & Lin, Z. (2022) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.9342 · Cited by 1
Devagi, G., Shanmugapriya, A., Ponnusamy, S., Kaminsky, W., Ruba, S., & Sathiyaraj, G. (2025) · ChemistrySelect · doi:10.1002/slct.202503243 · Cited by 1
Karpowicz, R., Steverding, D., Füllborn-Ott, J., Ott, I., Dhital, S., Albrecht, T., & Kowalski, K. (2026) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2026.124081 · Cited by 1
Chirality-Driven Immune Checkpoint Modulation by Chiral Iridium(III) Nanoparticles
Zhu, L., Wen, Z., Yu, M., Zhang, J., Qin, Y., Gao, S., Mao, Y., Deng, Y., Tian, T., Liu, S., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c00020 · Cited by 1
Zhu, Y., Li, Y., Jiang, Y., Fan, Z., & Liu, W. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00899 · Cited by 1
Ninh, N. H., Thong, P. V., Meervelt, L. V., & Thanh, N. T. (2025) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2025.114916 · Cited by 1
STING agonism in brain tumours: mechanisms, challenges, and therapeutic advances
Ioannou, Z., Cressey, P., Ahmed, M. H., Pouliopoulos, A. N., Hargrave, D. R., & Thanou, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1679361 · Cited by 1
“There is also an ongoing concern regarding the potential of development secondary immune-related cancers following metal-based drug therapy, thus limiting their overall therapeutic applications as indirectly acting STING agonists, despite their interaction with the pathway (97).”
Addressing Clinical Challenges of Platinum Anticancer Drugs through Rational Chemical Design
Zhang, S., & Guo, Z. (2026) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6c00342 · Cited by 1
Chen, Z., Xie, L., Wang, T., Liang, J., Chen, Y., & Chao, H. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00806 · Cited by 1
Anil, A. P., Tripathi, D. D., Nayak, S. S., Krishna, R., Kumar, U., Manimaran, B., & Sakthivel, N. (2026) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2026.110942 · Cited by 1
An overview on metal-doped carbon dots uses for biomedical applications
Ala, M., Aceves-Suriano, C. E., Bartoli, M., & Tagliaferro, A. (2025) · Materials Today Quantum · doi:10.1016/j.mtquan.2025.100030 · Cited by 1
Sayeh, A. M. A., & Rawashdeh, M. (2025) · Journal of Biomedicine and Biochemistry · doi:10.57238/jbb.2024.7432.1135 · Cited by 1
New insights into the anti-hepatoma mechanism of Alisol G-metal ions complexes based on c-myc DNA
Xu, F., Chen, J., Cai, L., Cao, H., Gu, W., Gu, W., & Zeng, L. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103425 · Cited by 1
Bioinspired Dinuclear Copper Complexes for Small Molecule Activation
Spyra, C.-J. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8804 · Cited by 1
Iadarola, P. (2019) · MDPI eBooks · doi:10.3390/books978-3-03897-827-5
Thanh, N. T. (2021) · Vietnam Journal of Chemistry · doi:10.1002/vjch.202000209
Metal complexes as chemotherapeutic agents
Deo, K. M., & Aldrich-Wright, J. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823144-9.00050-9
Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile
Contel, M. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-316-0 · Cited by 1
Sarkar, A., Novohradský, V., Maji, M., Babu, T., Marková, L., Kostrhunová, H., Kašpárková, J., Gandin, V., Brabec, V., & Gibson, D. (2023) · Angewandte Chemie · doi:10.1002/ange.202310774 · Cited by 1
Arjmand, F., Tabassum, S., & Khan, H. Y. (2024) · Springer eBooks · doi:10.1007/978-981-97-0146-9_1
Thong, P. V., Trang, D. N. D., Hang, T. T., & Thanh, N. T. (2024) · Vietnam Journal of Science and Technology/Science and Technology · doi:10.15625/2525-2518/18442
Adhikary, S. D., Roymahapatra, G., Chand, B. G., & Dinda, J. (2024) · ES chemistry and sustainability. · doi:10.30919/escs1360
Yang, J., Wang, F., Huang, S., Feng, T., Xiong, K., Chen, Y., & Chao, H. (2025) · Angewandte Chemie · doi:10.1002/ange.202505689
Metal speciation in blood plasmaPreprint
Prasad, A., & Shock, E. L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.04.680475 · Cited by 1
Trejo‐Solís, C., Fuentes-Noriega, I., Ortíz-Plata, A., Pineda, B., Macario‐Hernández, A., Castillo‐Rodríguez, R. A., Palomares‐Alonso, F., Romo‐Mancillas, A., Silva‐Adaya, D., Ruíz-Azuara, L., et al. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70132
PANapoptosis Elicited by Advanced Bismuth-Based Anticancer Drugs through Oxidative Damage
Liu, C., Yang, M., Li, R., Jiang, Y., Sun, D., Ouyang, R., Miao, Y., & Zhou, S. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02278
Role of nanocomposite for bladder cancer management
Sharma, H., Noman, A. A., Zohora, U. F. T., Ahmad, I., Pathak, R., & Kapoor, D. U. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36632-1.00009-2
Wang, F., Wang, Y., Zang, M., Du, Z., Zheng, W., Qiao, J., Wu, K., Luo, Q., Qi, L., Zhao, Y., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8574332/v1
Li, J. D., Song, F., Liu, J., Chen, Y., Zhang, J., Cao, M., Zeng, X., Wu, M., Miao, Y., Yao, L., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.202524447
Li, J. D., Song, F., Liu, J., Chen, Y., Zhang, J., Cao, M., Zeng, X., Wu, M., Miao, Y., Yao, L., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.202524447
Zaballa, A. M. L., de Oliveira, A. P. A., Fazzi, R. B., de Paiva, R. E. F., Tsantarlis, K., de Oliveira, C. C., Luz, M. S., Miyamoto, S., & Ferreira, A. C. P. (2026) · Frontiers in Chemical Biology · doi:10.3389/fchbi.2026.1666012
Wu, Q., & Xiao, Y. (2026) · Zeitschrift für Kristallographie - New Crystal Structures · doi:10.1515/ncrs-2026-0062
Drug potential of palladium(II) arsine complex: Experimental and theoretical analysis
Devarajan, B., Velusamy, K. M., Balaich, G. J., Maroli, N., & Ilanchelian, M. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146581
Metal‐Based Combination Therapies in Cancer: Mechanistic Principles and Emerging Opportunities
Xiong, X., Ren, J., & Wang, H. (2026) · Chemistry - A European Journal · doi:10.1002/chem.71514
Yang, L.-M., Levine, M. S., Wang, F.-Y., Tang, J.-Q., He, S., Feng, T., Lu, Y., Wang, Y., Zhang, W., Sessler, J. L., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c15572
Zhang, X., Santos, H. A., & Xia, B. (2026) · Advanced Functional Materials · doi:10.1002/adfm.78108
“Overall, this perspective highlights a fundamental role of coordination chemistry in governing Mn 2 + -based immunomodulators and establishes a conceptual framework for the emerging fields of metalloimmunology [ 19, 20 ] and next-generation precision metalloimmunotherapy [ 21–23 ].”
Metal natural product complexes as emerging anticancer chemoimmunotherapeutic agents
Chen, H., Cai, L., & Wang, X. (2026) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2026.09.003
Metadata
- Authors
- Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W.
- Affiliations
- Comprehensive Cancer Center Vienna (AT)
- University of Vienna (AT)
- Corresponding author
- Berger, Walter
- ORCID
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-11-29
- Volume
- 119
- Issue
- 2
- Pages
- 1519-1624
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2903051221
- Cited by
- 355
- References
- 1,298
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 47 · 2023: 51 · 2022: 49 · 2021: 45 · 2020: 53 · 2019: 38
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Chemical Reviews (publishedVersion)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Funders
- FP7 People: Marie-Curie Actions (609431)
- Universit?t Wien
- Medizinische Universit?t Wien
- Johanna Mahlke, geb. Obermann-Stiftung zur F?rderung der Krebsforschung an der Universit?t Wien
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- metal-based anticancer agents, antitumor immunity, immune surveillance, immune evasion, cancer immunotherapy, immune checkpoint inhibitors, tumor microenvironment, innate and adaptive immunity
- MeSH terms
- Gastrointestinal Microbiome, Antineoplastic Agents, Humans, Immunity, Innate, Immunotherapy, Lymphocytes, Metals, Neoplasms, Nanoparticles, Coordination Complexes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.